Bioporto A/S is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's segments include the NGAL Test, ELISA Human NGAL kits, ELISA Animal NGAL kits, ELISA MBL kits, Antibodies, and Other products and licenses. Bioporto generates majority of its revenues from Antibodies segment.